-
1
-
-
85048791183
-
-
The 31st Annual North American Cystic Fibrosis Conference, Indiana Convention Center, Indianapolis, Indiana, November 2-4, 2017., Pediatr Pulmonol Suppl
-
The 31st Annual North American Cystic Fibrosis Conference, Indiana Convention Center, Indianapolis, Indiana, November 2-4, 2017. Pediatr Pulmonol Suppl. 2017; 52:S1–S776.
-
(2017)
, vol.52
, pp. S1-S776
-
-
-
2
-
-
85028719507
-
FDA OKs first in vitro route to expanded approval
-
Kingwell K. FDA OKs first in vitro route to expanded approval. Nat Rev Drug Discov. 2017; 16:591–592.
-
(2017)
Nat Rev Drug Discov
, vol.16
, pp. 591-592
-
-
Kingwell, K.1
-
3
-
-
85008221944
-
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
-
Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017; 5:107–118.
-
(2017)
Lancet Respir Med
, vol.5
, pp. 107-118
-
-
Konstan, M.W.1
McKone, E.F.2
Moss, R.B.3
-
4
-
-
84943328860
-
Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data
-
Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192:836–842.
-
(2015)
Am J Respir Crit Care Med
, vol.192
, pp. 836-842
-
-
Sawicki, G.S.1
McKone, E.F.2
Pasta, D.J.3
-
5
-
-
0031804609
-
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design
-
Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998; 27:249–284.
-
(1998)
Annu Rev Biophys Biomol Struct
, vol.27
, pp. 249-284
-
-
Wlodawer, A.1
Vondrasek, J.2
-
6
-
-
85016073190
-
Molecular structure of the human CFTR ion channel
-
e88
-
Liu F, Zhang Z, Csanady L, Gadsby DC, Chen J. Molecular structure of the human CFTR ion channel. Cell. 2017; 169:85–95 e88.
-
(2017)
Cell
, vol.169
, pp. 85-95
-
-
Liu, F.1
Zhang, Z.2
Csanady, L.3
Gadsby, D.C.4
Chen, J.5
-
7
-
-
84974623218
-
Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma
-
Bonser LR, Zlock L, Finkbeiner W, Erle DJ. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest. 2016; 126:2367–2371.
-
(2016)
J Clin Invest
, vol.126
, pp. 2367-2371
-
-
Bonser, L.R.1
Zlock, L.2
Finkbeiner, W.3
Erle, D.J.4
-
8
-
-
85034765653
-
Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del
-
Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del. N Engl J Med. 2017; 377:2013–2023.
-
(2017)
N Engl J Med
, vol.377
, pp. 2013-2023
-
-
Taylor-Cousar, J.L.1
Munck, A.2
McKone, E.F.3
-
9
-
-
85034732149
-
Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis
-
Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017; 377:2024–2035.
-
(2017)
N Engl J Med
, vol.377
, pp. 2024-2035
-
-
Rowe, S.M.1
Daines, C.2
Ringshausen, F.C.3
-
10
-
-
84920412587
-
Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection
-
Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014; 11:1640–1650.
-
(2014)
Ann Am Thorac Soc
, vol.11
, pp. 1640-1650
-
-
Mogayzel, P.J.1
Naureckas, E.T.2
Robinson, K.A.3
-
11
-
-
85041129636
-
Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation
-
[Epub ahead of print]
-
Motwani MP, Bennett F, Norris PC, et al. Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation. Clin Pharmacol Ther. 2017. https://doi.org/10.1002/cpt.980. [Epub ahead of print].
-
(2017)
Clin Pharmacol Ther
-
-
Motwani, M.P.1
Bennett, F.2
Norris, P.C.3
-
12
-
-
85028300098
-
A low-molecular-weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness
-
Pritchard MF, Powell LC, Jack AA, et al. A low-molecular-weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness. Antimicrob Agents Chemother. 2017; 61. https://doi.org/10.1128/AAC.00762-17
-
(2017)
Antimicrob Agents Chemother
, vol.61
-
-
Pritchard, M.F.1
Powell, L.C.2
Jack, A.A.3
-
13
-
-
85016777444
-
The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption
-
Pritchard MF, Powell LC, Khan S, et al. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Sci Rep. 2017; 7:44731.
-
(2017)
Sci Rep
, vol.7
, pp. 44731
-
-
Pritchard, M.F.1
Powell, L.C.2
Khan, S.3
-
14
-
-
85014001279
-
Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial
-
De Boeck K, Haarman E, Hull J, et al. Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. J Cyst Fibros. 2017; 16:380–387.
-
(2017)
J Cyst Fibros
, vol.16
, pp. 380-387
-
-
De Boeck, K.1
Haarman, E.2
Hull, J.3
-
15
-
-
84880078608
-
Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis
-
Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013; 144:215–225.
-
(2013)
Chest
, vol.144
, pp. 215-225
-
-
Bilton, D.1
Daviskas, E.2
Anderson, S.D.3
-
16
-
-
84878360064
-
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis
-
Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013; 12:367–376.
-
(2013)
J Cyst Fibros
, vol.12
, pp. 367-376
-
-
Bilton, D.1
Bellon, G.2
Charlton, B.3
-
17
-
-
84858234304
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study
-
Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012; 185:645–652.
-
(2012)
Am J Respir Crit Care Med
, vol.185
, pp. 645-652
-
-
Aitken, M.L.1
Bellon, G.2
De Boeck, K.3
-
18
-
-
84994411660
-
Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling
-
DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V, Newman DK. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. MBio. 2016; 7.
-
(2016)
MBio
, vol.7
-
-
DePas, W.H.1
Starwalt-Lee, R.2
Van Sambeek, L.3
Ravindra Kumar, S.4
Gradinaru, V.5
Newman, D.K.6
-
19
-
-
84958211439
-
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
-
Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71:i1–i22.
-
(2016)
Thorax
, vol.71
, pp. i1-i22
-
-
Floto, R.A.1
Olivier, K.N.2
Saiman, L.3
-
20
-
-
84958206254
-
International committee on mental health in cystic fibrosis: cystic fibrosis foundation and european cystic fibrosis society consensus statements for screening and treating depression and anxiety
-
Quittner AL, Abbott J, Georgiopoulos AM, et al. International committee on mental health in cystic fibrosis: cystic fibrosis foundation and european cystic fibrosis society consensus statements for screening and treating depression and anxiety. Thorax. 2016; 71:26–34.
-
(2016)
Thorax
, vol.71
, pp. 26-34
-
-
Quittner, A.L.1
Abbott, J.2
Georgiopoulos, A.M.3
-
21
-
-
78650858488
-
Collaborative care for patients with depression and chronic illnesses
-
Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010; 363:2611–2620.
-
(2010)
N Engl J Med
, vol.363
, pp. 2611-2620
-
-
Katon, W.J.1
Lin, E.H.2
Von Korff, M.3
-
22
-
-
84896514136
-
The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement
-
Sabadosa KA, Batalden PB. The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement. BMJ Qual Saf. 2014; 23:i90–i94.
-
(2014)
BMJ Qual Saf
, vol.23
, pp. i90-i94
-
-
Sabadosa, K.A.1
Batalden, P.B.2
|